Clinical Trial Update: ADV-TK Improves Outcome of Recurrent High-Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial of ADV-TK in recurrent high-grade glioma reports improved outcomes in malignant glioma and glioblastoma. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• ADV-TK

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Malignant Glioma of Brain, Glioblastoma | Phase 2 | Status: COMPLETED